A randomized trial of carvedilol after renin-angiotensin system inhibition in chronic Chagas cardiomyopathy

In patients with chronic Chagas cardiomyopathy, optimization of treatment with enalapril and spironolactone and subsequent addition of carvedilol were safe and associated with benefits in cardiac function and clinical status. Larger trials are needed to show effects on mortality and/or hospitalization.